Drug Profile
Research programme: human papillomavirus infections - GPC Biotech/Boehringer Ingelheim
Alternative Names: HPV infections research programme - Boehringer Ingelheim/GPC Biotech; Human papillomavirus infections research programme - Boehringer Ingelheim/GPC BiotechLatest Information Update: 27 Apr 2004
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim; GPC Biotech AG
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Human papillomavirus infections
Most Recent Events
- 27 Apr 2004 Discontinued - Preclinical for Human papillomavirus infections in Canada (unspecified route)
- 27 Apr 2004 Discontinued - Preclinical for Human papillomavirus infections in Germany (unspecified route)
- 10 Jul 2002 GPC Biotech has received milestone payments from Boehringer Ingelheim